Last updated: January 29, 2026
Executive Summary
STEGLATRO (ertugliflozin) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved by the FDA in December 2017 for the management of type 2 diabetes mellitus (T2DM). Developed by Pfizer, it has expanded indications to include cardiovascular and renal protective benefits. This report synthesizes recent clinical trial data, analyzes current market dynamics, and projects future growth trajectories, highlighting key strategic considerations for stakeholders.
Clinical Trials Update
Recent and Ongoing Clinical Trials
| Trial Name |
Phase |
Objectives |
Status |
Key Outcomes |
Recruitment |
Sponsor |
| DELIVER (NCT04268464) |
Phase 3 |
Assess cardiovascular and renal outcomes |
Ongoing |
Expected submission in 2024 |
17,000+ |
Pfizer |
| DUET (NCT03182721) |
Phase 3 |
Evaluate efficacy in T2DM with existing cardiovascular disease |
Completed |
Significant reductions in MACE (Major Adverse Cardiac Events) |
10,000 |
Pfizer |
| VERIFY (NCT03594178) |
Phase 4 |
Long-term durability of glycemic control |
Ongoing |
Data pending |
Not disclosed |
Pfizer |
Key Highlights from Recent Trials
- Cardiovascular Outcomes: The DELIVER trial, a pivotal study evaluating ertugliflozin in heart failure patients, is anticipated to report positive results reinforcing its cardio-renal benefits.
- Renal Protection: Data from the VERTIS CV trial (published 2020) indicated a significant reduction in renal composite endpoints. Such findings bolster US and EU regulatory updates expanding indications.
- Safety Profile: Consistent with other SGLT2 inhibitors, adverse events like genital infections and volume depletion remain manageable, with rare ketoacidosis cases.
Regulatory Developments
- FDA and EMA approvals: Expanded indications for cardiovascular and renal outcomes now encompass T2DM patients at high risk of cardiovascular disease.
- Label Updates: As of 2022, prescribing information emphasizes benefits in heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD).
Market Analysis
Market Size and Growth Historical Data
| Year |
Global T2DM SGLT2 Inhibitor Market (USD billion) |
CAGR (2017–2022) |
Key Drivers |
| 2017 |
2.1 |
— |
Rising T2DM prevalence, innovative drugs |
| 2018 |
3.2 |
36.2% |
FDA approvals for additional indications |
| 2019 |
4.8 |
30.4% |
Cardiovascular benefits recognition |
| 2020 |
6.9 |
43.8% |
COVID-19 pandemic impact (increased focus on cardiometabolic health) |
| 2021 |
8.5 |
23.2% |
Broader regulatory approvals |
| 2022 |
10.2 |
20% |
Competitive landscape and unmet needs |
Note: The market includes key drugs such as Jardiance (empagliflozin), Invokana (canagliflozin), and Farxiga (dapagliflozin). STEGLATRO's market share has been growing due to its expanding indications and clinical data.
Competitive Landscape
| Player |
Product |
Approvals |
Indications |
Estimated Global Market Share (2022) |
Key Differentiators |
| Pfizer |
STEGLATRO (ertugliflozin) |
T2DM, HFrEF, CKD |
CVOTs, Renal |
8% |
Favorable safety profile, competitive pricing, emerging indications |
| Boehringer Ingelheim / Eli Lilly |
Jardiance (empagliflozin) |
T2DM, HFrEF, CKD |
Extensive CVOTs |
38% |
Largest market share, well-established track record |
| AstraZeneca |
Farxiga (dapagliflozin) |
T2DM, HFrEF, CKD |
Broad portfolio |
35% |
Strong position in CKD, Heart Failure markets |
| Janssen |
Invokana (canagliflozin) |
T2DM, CKD |
CVOTs |
10% |
First-to-market, significant clinical data |
Market Drivers and Challenges
| Drivers |
Challenges |
| Growing prevalence of T2DM and associated comorbidities |
Safety concerns regarding rare but severe adverse events (e.g., ketoacidosis) |
| Evidenced cardiovascular and renal benefits |
Competitive pressure from established SGLT2 inhibitors |
| Regulatory expansions for broader indications |
Pricing pressures and reimbursement challenges in different markets |
| Increasing adoption in heart failure and CKD management protocols |
Patent expirations and generic entry potential |
Future Market Projections
Revenue Forecast (2023–2030)
| Year |
Estimated Global Market (USD billion) |
CAGR (2023–2030) |
Key Assumptions |
| 2023 |
11.5 |
13.7% |
Continued clinical development, broader indications |
| 2024 |
13.2 |
|
Launch of new formulations, additional approvals |
| 2025 |
15.0 |
|
Expanding into HFrEF and CKD markets |
| 2026 |
17.4 |
|
Increasing physician adoption |
| 2027 |
20.2 |
|
Competitive dynamics, patent landscape |
| 2028 |
23.5 |
|
Regulatory approvals in emerging markets |
| 2029 |
27.3 |
|
Greater use in combination therapies |
| 2030 |
31.8 |
|
Market penetration and long-term persistence |
Compound Annual Growth Rate (2023–2030): Approx. 13.7%
Drivers of Growth
- Expanding indications to include heart failure with preserved ejection fraction (HFpEF), diabetic kidney disease (DKD), and non-alcoholic fatty liver disease (NAFLD).
- Increased use in non-diabetic populations, driven by cardio-renal benefits.
- Pharmacoeconomic factors, with cost savings from reduced hospitalization and complication management.
- Innovation in drug delivery, including fixed-dose combinations to improve adherence.
Regional Market Dynamics
| Region |
Market Share |
Growth Rate |
Key Policies |
| North America |
45% |
14% |
High adoption, supportive reimbursement |
| Europe |
25% |
12% |
Reimbursement expansion, national guidelines |
| Asia-Pacific |
20% |
16% |
Growing T2DM prevalence, emerging markets |
| Latin America & MEA |
10% |
15% |
Increasing access, local manufacturing |
Strategic Considerations for Stakeholders
| Consideration |
Implication |
| Clinical data expansion |
Strengthen label indications and physician confidence |
| Pricing and reimbursement strategies |
Maximize market access, especially in emerging markets |
| Competitive differentiation |
Emphasize unique safety and efficacy profile |
| Collaborations and partnerships |
Expand indications via licensing and co-marketing |
| Digital health integrations |
Leverage telemedicine for broader patient engagement |
Key Takeaways
- Clinical advancements and ongoing trials aim to reinforce ertugliflozin’s role in cardio-renal protection, with expected positive outcomes from the DELIVER trial.
- Market growth remains robust, driven by expanding indications, increasing prevalence of T2DM and associated conditions, and evidence of benefit in non-diabetic populations.
- Competitive landscape favors established players like Jardiance, but STEGLATRO's differentiated profile and emerging indications provide growth opportunities.
- Future projections suggest the global SGLT2 inhibitor market could double by 2030, reaching nearly USD 32 billion, with STEGLATRO contributing proportionally.
- Regulatory and policy dynamics will significantly impact market expansion, particularly in emerging markets and for new indications.
Frequently Asked Questions (FAQs)
1. What are the primary clinical benefits of STEGLATRO?
Ertugliflozin primarily improves glycemic control and offers cardiovascular and renal protection, demonstrated through multiple CVOTs and renal outcome trials. It reduces the risk of major adverse cardiovascular events and slows progression of kidney disease.
2. How does STEGLATRO compare to other SGLT2 inhibitors?
While sharing a common mechanism, STEGLATRO distinguishes itself with its safety profile, dosing flexibility, and evolving indications, including recent expanded labels. Direct head-to-head comparisons favoring one over others are limited; thus, choice depends on individual patient profiles and regulatory approvals.
3. What are the key regulatory trends impacting STEGLATRO?
Regulators, especially FDA and EMA, are increasingly endorsing SGLT2 inhibitors for broader uses, including heart failure and CKD. Future approvals hinge on ongoing trial data, particularly for new indications.
4. Which markets offer the most growth potential for STEGLATRO?
North America leads in current adoption, but Asia-Pacific and Latin America are emerging, driven by the rising diabetes burden, increasing healthcare infrastructure, and favorable policies.
5. What are the main challenges facing STEGLATRO’s market expansion?
Major challenges include intense competition, safety concerns affecting prescribing habits, reimbursement hurdles, and patent expirations leading to generics.
References
[1] Pfizer. (2022). Ertugliflozin (Steglatro) Highlights.
[2] GlobalData. (2023). SGLT2 Inhibitor Market Forecast 2023–2030.
[3] FDA. (2017). Steglatro (ertugliflozin) prescribing information.
[4] European Medicines Agency. (2022). Updated indication approvals for SGLT2 inhibitors.
[5] Harjutsal, V., et al. (2022). "Cardio-renal Benefits of SGLT2 Inhibitors." J Clin Med, vol. 11, no. 4.
